Home > > > > > Report Detail

Global Endometriosis Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Publisher Name :
Date: 11-Nov-2022
No. of pages: 114
Inquire Before Buying

Report Scope

This latest report researches the industry structure, revenue and gross margin. Major players' headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Endometriosis Drugs companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Endometriosis Drugs market. Further, it explains the major drivers and regional dynamics of the global Endometriosis Drugs market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

- AbbVie

- Astellas Pharma

- AstraZeneca

- Debiopharm Group

- Evotec

- Kissei Pharmaceutical

- Neurocrine Biosciences

- ObsEva

- Pfizer

- Repros Therapeutics

- Roivant Sciences

- Takeda Pharmaceutical Company

- ValiRx

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.

Endometriosis Drugs Segment by Type

- Hormonal Therapy

- Add-back Medication

- Progestogens

- Chinese Herbs

Endometriosis Drugs Segment by Application

- Hospitals

- Clinics

- Research Institutes

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Russia

- - Nordic Countries

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Endometriosis Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Endometriosis Drugs market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Endometriosis Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Endometriosis Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Endometriosis Drugs revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Endometriosis Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Endometriosis Drugs revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including AbbVie, Astellas Pharma, AstraZeneca, Debiopharm Group, Evotec, Kissei Pharmaceutical, Neurocrine Biosciences, ObsEva and Pfizer, etc.

Global Endometriosis Drugs Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Endometriosis Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Hormonal Therapy
1.2.3 Add-back Medication
1.2.4 Progestogens
1.2.5 Chinese Herbs
1.3 Market by Application
1.3.1 Global Endometriosis Drugs Market Growth Rate by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Institutes
1.4 Study Objectives
1.5 Years Considered
2 Market Perspective
2.1 Global Endometriosis Drugs Market Size (2017-2028)
2.2 Endometriosis Drugs Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028
2.3 Global Endometriosis Drugs Market Size by Region (2017-2022)
2.4 Global Endometriosis Drugs Market Size Forecast by Region (2023-2028)
2.5 Global Top Endometriosis Drugs Countries Ranking by Market Size
3 Endometriosis Drugs Competitive by Company
3.1 Global Endometriosis Drugs Revenue by Players
3.1.1 Global Endometriosis Drugs Revenue by Players (2017-2022)
3.1.2 Global Endometriosis Drugs Market Share by Players (2017-2022)
3.2 Global Endometriosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Endometriosis Drugs Revenue
3.4 Global Endometriosis Drugs Market Concentration Ratio
3.4.1 Global Endometriosis Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Endometriosis Drugs Revenue in 2021
3.5 Global Endometriosis Drugs Key Players Head office and Area Served
3.6 Key Players Endometriosis Drugs Product Solution and Service
3.7 Date of Enter into Endometriosis Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Endometriosis Drugs Breakdown Data by Type
4.1 Global Endometriosis Drugs Historic Revenue by Type (2017-2022)
4.2 Global Endometriosis Drugs Forecasted Revenue by Type (2023-2028)
5 Global Endometriosis Drugs Breakdown Data by Application
5.1 Global Endometriosis Drugs Historic Market Size by Application (2017-2022)
5.2 Global Endometriosis Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Endometriosis Drugs Revenue by Company (2020-2022)
6.2 North America Endometriosis Drugs Revenue by Type (2017-2028)
6.3 North America Endometriosis Drugs Revenue by Application (2017-2028)
6.4 North America Endometriosis Drugs Revenue by Country (2017-2028)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Endometriosis Drugs Revenue by Company (2020-2022)
7.2 Europe Endometriosis Drugs Revenue by Type (2017-2028)
7.3 Europe Endometriosis Drugs Revenue by Application (2017-2028)
7.4 Europe Endometriosis Drugs Revenue by Country (2017-2028)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Endometriosis Drugs Revenue by Company (2020-2022)
8.2 Asia Pacific Endometriosis Drugs Revenue by Type (2017-2028)
8.3 Asia Pacific Endometriosis Drugs Revenue by Application (2017-2028)
8.4 Asia Pacific Endometriosis Drugs Revenue by Region (2017-2028)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Endometriosis Drugs Revenue by Company (2020-2022)
9.2 Latin America Endometriosis Drugs Revenue by Type (2017-2028)
9.3 Latin America Endometriosis Drugs Revenue by Application (2017-2028)
9.4 Latin America Endometriosis Drugs Revenue by Country (2017-2028)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Endometriosis Drugs Revenue by Company (2020-2022)
10.2 Middle East and Africa Endometriosis Drugs Revenue by Type (2017-2028)
10.3 Middle East and Africa Endometriosis Drugs Revenue by Application (2017-2028)
10.4 Middle East and Africa Endometriosis Drugs Revenue by Country (2017-2028)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Endometriosis Drugs Products and Services
11.1.4 AbbVie Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.1.5 AbbVie Endometriosis Drugs SWOT Analysis
11.1.6 AbbVie Recent Developments
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Details
11.2.2 Astellas Pharma Business Overview
11.2.3 Astellas Pharma Endometriosis Drugs Products and Services
11.2.4 Astellas Pharma Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.2.5 Astellas Pharma Endometriosis Drugs SWOT Analysis
11.2.6 Astellas Pharma Recent Developments
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Endometriosis Drugs Products and Services
11.3.4 AstraZeneca Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.3.5 AstraZeneca Endometriosis Drugs SWOT Analysis
11.3.6 AstraZeneca Recent Developments
11.4 Debiopharm Group
11.4.1 Debiopharm Group Company Details
11.4.2 Debiopharm Group Business Overview
11.4.3 Debiopharm Group Endometriosis Drugs Products and Services
11.4.4 Debiopharm Group Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.4.5 Debiopharm Group Endometriosis Drugs SWOT Analysis
11.4.6 Debiopharm Group Recent Developments
11.5 Evotec
11.5.1 Evotec Company Details
11.5.2 Evotec Business Overview
11.5.3 Evotec Endometriosis Drugs Products and Services
11.5.4 Evotec Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.5.5 Evotec Endometriosis Drugs SWOT Analysis
11.5.6 Evotec Recent Developments
11.6 Kissei Pharmaceutical
11.6.1 Kissei Pharmaceutical Company Details
11.6.2 Kissei Pharmaceutical Business Overview
11.6.3 Kissei Pharmaceutical Endometriosis Drugs Products and Services
11.6.4 Kissei Pharmaceutical Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.6.5 Kissei Pharmaceutical Endometriosis Drugs SWOT Analysis
11.6.6 Kissei Pharmaceutical Recent Developments
11.7 Neurocrine Biosciences
11.7.1 Neurocrine Biosciences Company Details
11.7.2 Neurocrine Biosciences Business Overview
11.7.3 Neurocrine Biosciences Endometriosis Drugs Products and Services
11.7.4 Neurocrine Biosciences Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.7.5 Neurocrine Biosciences Endometriosis Drugs SWOT Analysis
11.7.6 Neurocrine Biosciences Recent Developments
11.8 ObsEva
11.8.1 ObsEva Company Details
11.8.2 ObsEva Business Overview
11.8.3 ObsEva Endometriosis Drugs Products and Services
11.8.4 ObsEva Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.8.5 ObsEva Endometriosis Drugs SWOT Analysis
11.8.6 ObsEva Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Endometriosis Drugs Products and Services
11.9.4 Pfizer Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.9.5 Pfizer Endometriosis Drugs SWOT Analysis
11.9.6 Pfizer Recent Developments
11.10 Repros Therapeutics
11.10.1 Repros Therapeutics Company Details
11.10.2 Repros Therapeutics Business Overview
11.10.3 Repros Therapeutics Endometriosis Drugs Products and Services
11.10.4 Repros Therapeutics Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.10.5 Repros Therapeutics Endometriosis Drugs SWOT Analysis
11.10.6 Repros Therapeutics Recent Developments
11.11 Roivant Sciences
11.11.1 Roivant Sciences Company Details
11.11.2 Roivant Sciences Business Overview
11.11.3 Roivant Sciences Endometriosis Drugs Products and Services
11.11.4 Roivant Sciences Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.11.5 Roivant Sciences Recent Developments
11.12 Takeda Pharmaceutical Company
11.12.1 Takeda Pharmaceutical Company Company Details
11.12.2 Takeda Pharmaceutical Company Business Overview
11.12.3 Takeda Pharmaceutical Company Endometriosis Drugs Products and Services
11.12.4 Takeda Pharmaceutical Company Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.12.5 Takeda Pharmaceutical Company Recent Developments
11.13 ValiRx
11.13.1 ValiRx Company Details
11.13.2 ValiRx Business Overview
11.13.3 ValiRx Endometriosis Drugs Products and Services
11.13.4 ValiRx Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022)
11.13.5 ValiRx Recent Developments
12 Endometriosis Drugs Market Dynamics
12.1 Endometriosis Drugs Market Trends
12.2 Endometriosis Drugs Market Drivers
12.3 Endometriosis Drugs Market Challenges
12.4 Endometriosis Drugs Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
List of Tables
Table 1. Global Endometriosis Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Hormonal Therapy
Table 3. Key Players of Add-back Medication
Table 4. Key Players of Progestogens
Table 5. Key Players of Chinese Herbs
Table 6. Global Endometriosis Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 7. Global Endometriosis Drugs Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028
Table 8. Global Endometriosis Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 9. Global Endometriosis Drugs Revenue Market Share by Region (2017-2022)
Table 10. Global Endometriosis Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 11. Global Endometriosis Drugs Market Share by Players (2017-2022)
Table 12. Global Top Endometriosis Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endometriosis Drugs as of 2021)
Table 13. Ranking of Global Top Endometriosis Drugs Companies by Revenue (US$ Million) in 2021
Table 14. Global 5 Largest Players Market Share by Endometriosis Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 15. Key Players Headquarters and Area Served
Table 16. Key Players Endometriosis Drugs Product Solution and Service
Table 17. Date of Key Manufacturers Enter into Endometriosis Drugs Market
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. Global Endometriosis Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 20. Global Endometriosis Drugs Revenue Market Share by Type (2017-2022)
Table 21. Global Endometriosis Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 22. Global Endometriosis Drugs Revenue Market Share by Type (2023-2028)
Table 23. Global Endometriosis Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 24. Global Endometriosis Drugs Revenue Market Share by Application (2017-2022)
Table 25. Global Endometriosis Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 26. Global Endometriosis Drugs Revenue Market Share by Application (2023-2028)
Table 27. North America Endometriosis Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 28. North America Endometriosis Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 29. North America Endometriosis Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 30. North America Endometriosis Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 31. North America Endometriosis Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 32. North America Endometriosis Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 33. North America Endometriosis Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 34. Europe Endometriosis Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 35. Europe Endometriosis Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 36. Europe Endometriosis Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 37. Europe Endometriosis Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 38. Europe Endometriosis Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 39. Europe Endometriosis Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 40. Europe Endometriosis Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 41. Asia Pacific Endometriosis Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 42. Asia Pacific Endometriosis Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 43. Asia Pacific Endometriosis Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 44. Asia Pacific Endometriosis Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 45. Asia Pacific Endometriosis Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 46. Asia Pacific Endometriosis Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 47. Asia Pacific Endometriosis Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 48. Latin America Endometriosis Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 49. Latin America Endometriosis Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 50. Latin America Endometriosis Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 51. Latin America Endometriosis Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 52. Latin America Endometriosis Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 53. Latin America Endometriosis Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 54. Latin America Endometriosis Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Endometriosis Drugs Revenue by Company (2020-2022) & (US$ Million)
Table 56. Middle East and Africa Endometriosis Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Endometriosis Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Endometriosis Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Endometriosis Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Endometriosis Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Endometriosis Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 62. AbbVie Company Details
Table 63. AbbVie Business Overview
Table 64. AbbVie Endometriosis Drugs Product and Services
Table 65. AbbVie Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 66. AbbVie Endometriosis Drugs SWOT Analysis
Table 67. AbbVie Recent Developments
Table 68. Astellas Pharma Company Details
Table 69. Astellas Pharma Business Overview
Table 70. Astellas Pharma Endometriosis Drugs Product and Services
Table 71. Astellas Pharma Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 72. Astellas Pharma Endometriosis Drugs SWOT Analysis
Table 73. Astellas Pharma Recent Developments
Table 74. AstraZeneca Company Details
Table 75. AstraZeneca Business Overview
Table 76. AstraZeneca Endometriosis Drugs Product and Services
Table 77. AstraZeneca Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 78. AstraZeneca Endometriosis Drugs SWOT Analysis
Table 79. AstraZeneca Recent Developments
Table 80. Debiopharm Group Company Details
Table 81. Debiopharm Group Business Overview
Table 82. Debiopharm Group Endometriosis Drugs Product and Services
Table 83. Debiopharm Group Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 84. Debiopharm Group Endometriosis Drugs SWOT Analysis
Table 85. Debiopharm Group Recent Developments
Table 86. Evotec Company Details
Table 87. Evotec Business Overview
Table 88. Evotec Endometriosis Drugs Product and Services
Table 89. Evotec Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 90. Evotec Endometriosis Drugs SWOT Analysis
Table 91. Evotec Recent Developments
Table 92. Kissei Pharmaceutical Company Details
Table 93. Kissei Pharmaceutical Business Overview
Table 94. Kissei Pharmaceutical Endometriosis Drugs Product and Services
Table 95. Kissei Pharmaceutical Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 96. Kissei Pharmaceutical Endometriosis Drugs SWOT Analysis
Table 97. Kissei Pharmaceutical Recent Developments
Table 98. Neurocrine Biosciences Company Details
Table 99. Neurocrine Biosciences Business Overview
Table 100. Neurocrine Biosciences Endometriosis Drugs Product and Services
Table 101. Neurocrine Biosciences Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 102. Neurocrine Biosciences Endometriosis Drugs SWOT Analysis
Table 103. Neurocrine Biosciences Recent Developments
Table 104. ObsEva Company Details
Table 105. ObsEva Business Overview
Table 106. ObsEva Endometriosis Drugs Product and Services
Table 107. ObsEva Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 108. ObsEva Endometriosis Drugs SWOT Analysis
Table 109. ObsEva Recent Developments
Table 110. Pfizer Company Details
Table 111. Pfizer Business Overview
Table 112. Pfizer Endometriosis Drugs Product and Services
Table 113. Pfizer Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 114. Pfizer Endometriosis Drugs SWOT Analysis
Table 115. Pfizer Recent Developments
Table 116. Repros Therapeutics Company Details
Table 117. Repros Therapeutics Business Overview
Table 118. Repros Therapeutics Endometriosis Drugs Product and Services
Table 119. Repros Therapeutics Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 120. Repros Therapeutics Endometriosis Drugs SWOT Analysis
Table 121. Repros Therapeutics Recent Developments
Table 122. Roivant Sciences Company Details
Table 123. Roivant Sciences Business Overview
Table 124. Roivant Sciences Endometriosis Drugs Product and Services
Table 125. Roivant Sciences Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 126. Roivant Sciences Recent Developments
Table 127. Takeda Pharmaceutical Company Company Details
Table 128. Takeda Pharmaceutical Company Business Overview
Table 129. Takeda Pharmaceutical Company Endometriosis Drugs Product and Services
Table 130. Takeda Pharmaceutical Company Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 131. Takeda Pharmaceutical Company Recent Developments
Table 132. ValiRx Company Details
Table 133. ValiRx Business Overview
Table 134. ValiRx Endometriosis Drugs Product and Services
Table 135. ValiRx Endometriosis Drugs Revenue in Endometriosis Drugs Business (2017-2022) & (US$ Million)
Table 136. ValiRx Recent Developments
Table 137. Endometriosis Drugs Market Trends
Table 138. Endometriosis Drugs Market Drivers
Table 139. Endometriosis Drugs Market Challenges
Table 140. Endometriosis Drugs Market Restraints
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Endometriosis Drugs Sales Market Share by Type: 2021 VS 2028
Figure 2. Hormonal Therapy Features
Figure 3. Add-back Medication Features
Figure 4. Progestogens Features
Figure 5. Chinese Herbs Features
Figure 6. Global Endometriosis Drugs Sales Market Share by Application: 2021 VS 2028
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Research Institutes Case Studies
Figure 10. Endometriosis Drugs Report Years Considered
Figure 11. Global Endometriosis Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Endometriosis Drugs Market Size 2017-2028 (US$ Million)
Figure 13. Global Endometriosis Drugs Market Size Market Share by Region: 2021 VS 2028
Figure 14. Global Endometriosis Drugs Revenue Market Share by Region in 2017 VS 2022
Figure 15. Global Top 10 Endometriosis Drugs Countries Ranking by Market Size (US$ Million) in 2021
Figure 16. Global Endometriosis Drugs Market Share by Players in 2021
Figure 17. Global Top Endometriosis Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endometriosis Drugs as of 2021)
Figure 18. The Top 10 and 5 Players Market Share by Endometriosis Drugs Revenue in 2021
Figure 19. North America Endometriosis Drugs Revenue Market Share by Company in 2021
Figure 20. North America Endometriosis Drugs Revenue Market Share by Type (2017-2028)
Figure 21. North America Endometriosis Drugs Revenue Market Share by Application (2017-2028)
Figure 22. North America Endometriosis Drugs Revenue Share by Country (2017-2028)
Figure 23. U.S. Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 24. Canada Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 25. Europe Endometriosis Drugs Revenue Market Share by Company in 2021
Figure 26. Europe Endometriosis Drugs Revenue Market Share by Type (2017-2028)
Figure 27. Europe Endometriosis Drugs Revenue Market Share by Application (2017-2028)
Figure 28. Europe Endometriosis Drugs Revenue Share by Country (2017-2028)
Figure 29. Germany Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 30. France Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 31. U.K. Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 32. Italy Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 33. Russia Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 34. Asia Pacific Endometriosis Drugs Revenue Market Share by Company in 2021
Figure 35. Asia Pacific Endometriosis Drugs Revenue Market Share by Type (2017-2028)
Figure 36. Asia Pacific Endometriosis Drugs Revenue Market Share by Application (2017-2028)
Figure 37. Asia Pacific Endometriosis Drugs Revenue Share by Region (2017-2028)
Figure 38. China Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 39. Japan Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 40. South Korea Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 41. India Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 42. Australia Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 43. Taiwan Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 44. Indonesia Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 45. Thailand Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 46. Malaysia Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 47. Philippines Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 48. Vietnam Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 49. Latin America Endometriosis Drugs Revenue Market Share by Company in 2021
Figure 50. Latin America Endometriosis Drugs Revenue Market Share by Type (2017-2028)
Figure 51. Latin America Endometriosis Drugs Revenue Market Share by Application (2017-2028)
Figure 52. Latin America Endometriosis Drugs Revenue Share by Country (2017-2028)
Figure 53. Mexico Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 54. Brazil Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 55. Argentina Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 56. Middle East and Africa Endometriosis Drugs Revenue Market Share by Company in 2021
Figure 57. Middle East and Africa Endometriosis Drugs Revenue Market Share by Type (2017-2028)
Figure 58. Middle East and Africa Endometriosis Drugs Revenue Market Share by Application (2017-2028)
Figure 59. Middle East and Africa Endometriosis Drugs Revenue Share by Country (2017-2028)
Figure 60. Turkey Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 61. Saudi Arabia Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 62. U.A.E Endometriosis Drugs Revenue (2017-2028) & (US$ Million)
Figure 63. AbbVie Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 64. Astellas Pharma Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 65. AstraZeneca Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 66. Debiopharm Group Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 67. Evotec Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 68. Kissei Pharmaceutical Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 69. Neurocrine Biosciences Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 70. ObsEva Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 71. Pfizer Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 72. Repros Therapeutics Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 73. Roivant Sciences Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 74. Takeda Pharmaceutical Company Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 75. ValiRx Revenue Growth Rate in Endometriosis Drugs Business (2017-2022)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
  • Global Drugs for Vulvovaginal Candidiasis Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119
    According to our LPI (LP Information) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at US$ 798.8 million in 2023. With growing demand in downstream market, the Drugs for Vulvovaginal Candidiasis is forecast to a readjusted size of US$ 890 million by 2030 with a CAGR of 1.6% during review period. The research report highlights the growth potential of the global Drugs for Vulvovaginal Candidiasis market. Drugs for Vulvovaginal Candidiasis are expected t......
  • Global Bacterial Vaginosis Drug Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 132
    According to our LPI (LP Information) latest study, the global Bacterial Vaginosis Drug market size was valued at US$ 896.6 million in 2023. With growing demand in downstream market, the Bacterial Vaginosis Drug is forecast to a readjusted size of US$ 1111.1 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Bacterial Vaginosis Drug market. Bacterial Vaginosis Drug are expected to show stable growth in the future ma......
  • Global Contraceptives Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 141
    According to our LPI (LP Information) latest study, the global Contraceptives market size was valued at US$ 1870.3 million in 2023. With growing demand in downstream market, the Contraceptives is forecast to a readjusted size of US$ 2237.4 million by 2030 with a CAGR of 2.6% during review period. The research report highlights the growth potential of the global Contraceptives market. Contraceptives are expected to show stable growth in the future market. However, product differentiation,......
  • Global Drugs for Vulvovaginal Candidiasis Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 108
    According to our (Global Info Research) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at USD 840.2 million in 2023 and is forecast to a readjusted size of USD 928.4 million by 2030 with a CAGR of 1.4% during review period. The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cu......
  • Global Menopausal Hot Flashes Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Menopausal Hot Flashes market: According to our latest research, the global Menopausal Hot Flashes market looks promising in the next 5 years. As of 2022, the global Menopausal Hot Flashes market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Hot flashes during menopause are symptoms of menopause. They refer to the warmth that occurs during the transition period of ......
  • Global Bacterial Vaginosis Drug Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 139
    Report Overview: This report studies the Bacterial Vaginosis Drug market, Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. This report includes metronidazole, clindamycin drug and other drugs. The Global Bacterial Vaginosis Drug Market Size was estimated at USD 916.50 million in 2022 and is projected to reach USD 1127.18 million by 202......
  • Global Drugs for Vulvovaginal Candidiasis Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 122
    Report Overview: The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for a......
  • Global Bacterial Vaginosis Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 108
    Market Overview of Global Bacterial Vaginosis Drug market: According to our latest research, the global Bacterial Vaginosis Drug market looks promising in the next 5 years. As of 2022, the global Bacterial Vaginosis Drug market was estimated at USD 972.77 million, and it's anticipated to reach USD 1215.68 million in 2028, with a CAGR of 3.79% during the forecast years. Bacterial vaginosis (BV), also known as bacterial vaginosis, non-specific vaginitis is a disease that occurs......
  • Global Tocolysis Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 123
    Market Overview of Global Tocolysis Drugs market: According to our latest research, the global Tocolysis Drugs market looks promising in the next 5 years. As of 2022, the global Tocolysis Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Tocolytics are medications used to suppress premature labor. Tocolytic therapy is provided when delivery would result in premature birth, postponi......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs